https://www.youtube.com/watch?v=axuIDgf1hkE Pulmonary fibrosis (PF) is a respiratory disease characterized by the formation of scarred tissue in the lungs, specifically in the air sacs known as alveoli. However, being a rare disease that affects about five million people throughout the world, pulmonary fibrosis is often away from the spotlight, which leads to…
Pulmonologist Dr. Eli Colon Explains What Pulmonary Fibrosis is
What is idiopathic pulmonary fibrosis (IPF)? IPF is a rare lung disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. This scarring of the lung tissue causes IPF patients to experience severe difficulties in breathing among other serious symptoms. In this animated…
The Pulmonary Fibrosis Foundation (PFF) is a 501(c)(3) nonprofit organization focused on fighting pulmonary fibrosis (PF). But how did it all start? The brothers Albert Rose and Michael Rosenzweigh, PhD, watched their sister suffer from the rare lung condition, and they ended up being diagnosed with it as well,…
https://vimeo.com/169933079 Pulmonary fibrosis is a disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. Most of the time, the cause of how it develops is unknown and in those cases, it’s called idiopathic (unknown cause) pulmonary fibrosis. In this video, shared by Institute of…
The Germany-based global pharmaceutical company Boehringer Ingelheim recently announced the establishment of a research alliance with the Harvard Stem Cell Institute (HSCI) to discover new targets for treating fibrotic diseases, such as chronic kidney disease (CKD), nonalcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF). The collaborative project, called Harvard Fibrosis Network, is…
1. Aoife Clancy Musician Aoife Clancy was famous for being a member of the band Cherish the Ladies. On September 6th, 2002, she lost her father to pulmonary fibrosis after a three-year struggle with the disease. Aoife and Bobby Clancy had a close relationship as he was the one that…
New York City-based Kadmon Corp., a biopharma focused on developing therapies for significant unmet medical needs, recently announced the start of the first dosing regimen in a patient in its Phase 2 clinical trial assessing the drug KD025, the company’s rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of idiopathic pulmonary fibrosis…
Germany based Boehringer Ingelheim and France based Inventiva have announced a new multi-year research and drug discovery collaboration and licensing agreement. Under the agreement, Inventiva and Boehringer Ingelheim teams will work on validation of a new therapeutic concept to discover new medicines for treating idiopathic pulmonary fibrosis (IPF) and other…
A recent study from Korea indicates that sublobar resection is less likely to result in death compared to a lobar resection for lung cancer patients with idiopathic pulmonary fibrosis. The research report, “Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with…
Boehringer Ingelheim and Inventiva recently signed a new multi-year drug discovery and research partnership and licensing agreement. Research teams from both companies will jointly work to validate a new therapeutic concept with the purpose of finding novel therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The…
